CRISPR Therapeutics Reports Positive Phase 1a Data for CTX310 at ESC 2026

Key Facts

1Phase 1a data for CTX310 showed sustained reductions in triglycerides by 48% and LDL by 53% at the highest dose.

2Results were presented at the ESC Congress 2026 and simultaneously published in The New England Journal of Medicine.

3The gene therapy was well tolerated with no treatment-related serious adverse events reported.

In a move reflecting the rapid evolution of biotechnology in treating cardiovascular diseases, CRISPR Therapeutics has unveiled strong clinical results. Phase 1a data for CTX310 demonstrated sustained reductions in triglycerides by 48% and LDL cholesterol by 53% at the highest dose level. These findings were presented during a late-breaking session at the ESC Congress 2026 and simultaneously published in The New England Journal of Medicine.

According to technical reports, the gene therapy was well tolerated by participating patients, with no treatment-related serious adverse events reported. The innovation utilizes CRISPR/Cas9 technology to edit the ANGPTL3 gene, offering the potential for deep and durable lipid lowering over a one-year period. These results strengthen the company's position in developing gene therapies targeting large-market cardiovascular indications.

Regarding market performance, updated price data for CRSP is currently unavailable (close August 28, 2026), requiring traders to monitor market reaction at the next opening. On the economic calendar, while no direct upcoming catalysts for the company are listed, investors will be watching for continued progress in Phase 1b clinical trials following this positive data.